PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs TRVN's -24.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy ≥ 1.5x TRVN's -14.00%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
≥ 1.5x TRVN's -13.07%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.82%
Below half TRVN's 166.51%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
≥ 1.5x TRVN's 88.79%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
≥ 1.5x TRVN's -10.79%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-28.35%
50-75% of TRVN's -51.40%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
Less than half of TRVN's 3.70%. David Dodd sees fewer expansions in other current obligations.
-23.54%
Less than half of TRVN's 11.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
Less than half of TRVN's 1.57%. David Dodd sees far fewer liability expansions relative to competitor.
2.39%
50-75% of TRVN's 3.51%. Bruce Berkowitz notes minimal new equity relative to competitor.
-4.88%
0.5-0.75x TRVN's -6.67%. Martin Whitman is wary of weaker retention or lower profitability.
-7.49%
Less than half of TRVN's -16.33%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
≥ 1.5x TRVN's -17.38%. David Dodd sees stronger capital base growth than competitor.
-28.88%
≥ 1.5x TRVN's -10.79%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
50-75% of TRVN's 50.63%. Bruce Berkowitz notes comparatively lower net debt expansion.